Inovio Pharmaceuticals, Inc. (NASDAQ:INO) marched up 0.91% compared to a 52-week low price of $3.31. The shares were last seen trading -5.92% lower, taking the closing price at $3.34 on 3/8/2019. At a recent session, the prices were hovering between $3.33 and $3.54. This company shares are 219.46% off its target price of $10.67 and the current market capitalization stands at $338.51M. The recent change has given its price a -23.58% deficit over SMA 50 and -46.98% deficit over its 52-week high. The stock witnessed -28.63% declines, -36.02% declines and -39.71% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found INO’s volatility during a week at 6.16% and during a month it has been found around 4.25%.Inovio Pharmaceuticals, Inc. (INO) Top Holders
Institutional investors currently hold around $119 million or 38.2% in INO stock. Look at its top three institutional owners: Blackrock Inc. owns $24.22 million in Inovio Pharmaceuticals, Inc., which represents roughly 7.16% of the company’s market cap and approximately 20.35% of the institutional ownership. Similar statistics are true for the second largest owner, Wasatch Advisors Inc, which owns 5,337,930 shares of the stock are valued at $17.83 million. The third largest holder is Vanguard Group Inc, which currently holds $15.19 million worth of this stock and that ownership represents nearly 4.49% of its market capitalization.Inovio Pharmaceuticals, Inc. 13F Filings
At the end of December reporting period, 60 institutional holders increased their position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by some 4,606,229 shares, 52 decreased positions by 1,803,520 and 34 held positions by 29,158,072. That puts total institutional holdings at 35,567,821 shares, according to SEC filings. The stock grabbed 20 new institutional investments totaling 985,326 shares while 23 institutional investors sold out their entire positions totaling 902,275 shares.Inovio Pharmaceuticals, Inc. (INO) Analyst Guide
Several analysts have released their opinion on Inovio Pharmaceuticals, Inc. (NASDAQ:INO), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation [T1].